Alli Covington, M.A. ❤️❤️❤️
70.2K posts

Alli Covington, M.A. ❤️❤️❤️
@allicovington
Founder, CEO of BOD Care | Performance Coach | Mental & Physical Performance System for B2B | mom of 3, wife of @_chriscovington


We should federally tax Tokens at the Provider level. Not a lot. Less than 50c per million tokens. It will accomplish 4 things (at least ) 1. It will push the big AI players to optimize tokenization, caching , routing and localization Which will 2. Reduce energy usage. Saving them in energy costs more than what they paid in tax and reducing strain created by the growth in energy consumption Which will 3. Generate maybe 10 billion dollars a year to start, but over the next ten years could grow 30x to 100x Which will 4. Create a source of funding to pay down the federal debt or deploy, in response to the things AI brings that we don’t expect or don’t like At some point the models will pass it on to customers. Of course. That’s ok. Customers will have the ability to choose between providers. Or to do everything using open source models locally. Thoughts ?












My general, "well supported" numbers, that I feel comfortable putting out there

A new episode of The Neuro Experience podcast just dropped. I sat down with @ariel_garten, founder and CEO of Muse, to talk about sleep, brain health, and neurodegenerative disease prevention.


1 in 3 college aged kids being on psych meds is absolutely bonkers We’ve completely lost the plot

Great question and visual, @realpeptides — the GLP-1 ecosystem is currently dominating, but the long game may look very different. GLP-1s (and multi-agonists) excel at population-level obesity and metabolic disease because they powerfully address appetite, gastric emptying, and insulin dynamics. Their projected user numbers make sense given the scale of the obesity epidemic. However, non-GLP peptides shine in specialized niches where GLP-1s are weaker: - Tissue repair & recovery (BPC-157, TB-500) - Skin rejuvenation & anti-aging (GHK-Cu) - Targeted growth hormone axis optimization (Tesamorelin, CJC-1295, Ipamorelin) - Mitochondrial & metabolic fine-tuning (MOTS-C, 5-Amino-1MQ) - Neuroprotection and cognitive support In 5+ years we’ll likely see a **bifurcated market**: GLP-1s as the broad metabolic “hammer,” and a rich ecosystem of targeted peptides for longevity, regeneration, performance, and specific disease states. The real winners will be those who combine both strategically. The peptide race isn’t zero-sum — it’s about stacking complementary tools for optimal human outcomes. #PeptideRace #GLP1 #NonGLPPeptides #Longevity #RegenerativeMedicine #Biohacking #MetabolicHealth #FutureOfPeptides





Let me explain how this works in real life A PHQ2 score is collected on almost every patient that walks in the door of a primary care clinic. At best, a PHQ9 Posted both here for your viewing pleasure TWO questions asked ONE time and MDD is “likely”. 9 questions seals it





